Maynard Um
-
-
-
-
-
-
-
Cognition Therapeutics advances DLB psychosis program for zervimesine
-
-
-
-
-
-
-
Cognition Therapeutics reaches 75% enrollment in Alzheimer's drug trial
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
-
-
-
-
-
-
-
Cognition Therapeutics (CGTX) PT Lowered to $5 at H.C. Wainwright
-
-
-
-
-
-
-
Cognition Therapeutics (CGTX) Reports Positive Results in Phase 2 Study of CT1812
-
-
-
-
-
-
-
B.Riley Downgrades Cognition Therapeutics (CGTX) to Neutral
-
-
-
-
404,946 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

